Related Experiment Video
Updated: Jul 16, 2026

05:49
An Automated Squint Method for Time-syncing Behavior and Brain Dynamics in Mouse Pain Studies
Published on: November 1, 2024
Analysis of responses in migraine modelling using hidden Markov models
Vladimir V Anisimov1, Hugo J Maas, Meindert Danhof
1Research Statistics Unit, Biomedical Data Sciences, GlaxoSmithKline, New Frontiers Science Park (South), Third Avenue, Harlow, Essex CM19 5AW, UK.
Statistics in Medicine
|March 27, 2007
Summary
This study introduces a new method for calculating confidence intervals in disease progression models. The approach enhances predictions for anti-migraine treatments, showing greater uncertainty for drug responses compared to placebo.
Area of Science:
- Biostatistics
- Pharmacometrics
- Mathematical Modeling
Background:
- Markov-type models are utilized for disease progression analysis.
- Existing software often lacks functionality for confidence intervals around predicted response variables.
- Accurate prediction intervals are crucial for evaluating treatment efficacy.
Purpose of the Study:
- To present a novel method for calculating means and confidence intervals of predicted responses over time.
- To apply this method to a non-homogeneous hidden Markov model in continuous time.
- To assess prediction uncertainty in clinical studies for anti-migraine treatments.
Main Methods:
- Utilizing Kolmogorov equations as the basis for calculations.
- Implementing the method in S-Plus software.
- Numerically solving non-linear differential equations for prediction intervals.
Main Results:
- The developed method successfully calculates means and confidence intervals for predicted responses.
- Uncertainty in predicted drug responses is greater than in predicted placebo responses.
- Pain-free responses are predicted with less precision than pain-relief responses.
Conclusions:
- The method provides essential confidence intervals for model-predicted responses, addressing a gap in current software.
- The findings highlight increased prediction uncertainty for drug treatments due to parameter variability.
- This approach offers a more nuanced understanding of treatment effects and their associated uncertainties in clinical trials.

